<DOC>
	<DOCNO>NCT01435213</DOCNO>
	<brief_summary>The purpose study validate [ 11C ] ORM-13070 alpha2C-adrenoceptor imaging agent human positron emission tomography ( PET ) study brain alpha2C-adrenoceptor occupancy .</brief_summary>
	<brief_title>Competition With Striatal 11CORM-13070 Binding Atipamezole Endogenous Noradrenaline</brief_title>
	<detailed_description />
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<mesh_term>Norepinephrine</mesh_term>
	<mesh_term>Atipamezole</mesh_term>
	<criteria>Written inform consent ( IC ) obtain . Good general health ascertain detailed medical history , laboratory investigation physical examination . Males 20 40 year age ( inclusive ) . Body mass index ( BMI ) 1828 kg/m2 inclusive ( BMI = weight/height2 ) . Weight 60100 kg ( inclusive ) . Suspected poor compliance protocol inability communicate well study personnel . Veins unsuitable repeated venipuncture . CYP2D6 slow metabolizer ultrarapid metabolizer genotype . Evidence clinically significant cardiovascular , renal , hepatic , haematological , gastrointestinal , pulmonary , metabolicendocrine , neurological , urogenital psychiatric disease judge investigator . Any condition require regular concomitant medication include herbal product likely need concomitant medication study . Susceptibility severe allergic reaction . Intake medication could affect outcome study , within 2 week prior tracer administration ( 2 month enzyme induce drug like rifampicin carbamazepine ) , less 5 time halflife medication . Regular consumption 21 unit alcohol per week ( 1 unit = 4 cl spirit , 13 g alcohol ) . Current use nicotinecontaining product 5 cigarette equivalent/day . Inability refrain use nicotinecontaining product stay study centre . Inability refrain consume caffeinecontaining beverage stay study centre , e.g . propensity headache refrain caffeinecontaining beverage . Blood donation loss significant amount blood within 2 month prior screen visit . Abnormal 12lead electrocardiogram ( ECG ) find clinical relevance 10 minute rest supine position screen visit , example : QTc ( calculate use Bazett 's formula ) &gt; 450 msec , PR &lt; 120 msec &gt; 210 msec , QRS &lt; 70 msec &gt; 120 msec . Heart rate ( HR ) &lt; 40 beats/minute &gt; 90 beats/minute 10 minute rest supine position screen visit . At screen visit , systolic blood pressure ( BP ) &lt; 90 mmHg &gt; 140 mmHg 10 minute supine position , diastolic BP &lt; 50 mmHg &gt; 90 mmHg 10 minute supine position . Any abnormal laboratory value , vital sign physical examination result , may opinion investigator interfere interpretation test result cause health risk subject take part study . History drug abuse positive result drug abuse test . Positive serology human immunodeficiency virus antibody ( HIVAb ) , hepatitis B surface antigen ( HBsAg ) hepatitis C virus antibody ( HCVAb ) . Anatomical abnormality brain MRI may opinion investigator interfere interpretation PET result . Any condition opinion investigator would interfere evaluation result constitute health risk subject . Participation another clinical drug study within 3 month prior study . Participation prior PET study medical occupational exposure significant dose ionize radiation . Any contraindication MRI brain .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>alpha2-adrenoceptor</keyword>
	<keyword>receptor occupancy</keyword>
	<keyword>positron emission tomography</keyword>
	<keyword>[ 11C ] ORM-13070</keyword>
	<keyword>striatum</keyword>
	<keyword>brain</keyword>
	<keyword>noradrenaline</keyword>
	<keyword>norepinephrine</keyword>
	<keyword>endogenous</keyword>
	<keyword>binding</keyword>
	<keyword>Validation study</keyword>
</DOC>